Molecular characterisation of cell line models for triple-negative breast cancers. - Wikidata - awgldk - TriplyDB

Molecular characterisation of cell line models for triple-negative breast cancers.

Molecular characterisation of cell line models for triple-negative breast cancers.

http://www.wikidata.org/entity/Q34476551

about

MDA-MB-468 MDA-MB-231 HCC1937 BT-20 BT-474 BT-483 BT-549 HCC1143 HCC1187 HCC1428 HCC1569 HCC1954 HCC38 HCC70 Hs 578T MDA-MB-157 MDA-MB-436 SUM1315MO2 SUM149PT SUM159PT SUM190PT SUM225CWN T-47D ZR-75-30 SK-BR-3

P1343

Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer.Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.Cell shape and the microenvironment regulate nuclear translocation of NF-κB in breast epithelial and tumor cells.Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs.Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. .Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.Selective isolation and characterization of primary cells from normal breast and tumors reveal plasticity of adipose derived stem cells.Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities.Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer.Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1 Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.Dynamic architecture of the purinosome involved in human de novo purine biosynthesis.Identification of clinically predictive metagenes that encode components of a network coupling cell shape to transcription by image-omics.Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile.Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis.Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-κB signaling in triple-negative breast cancer cells.Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments.Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.Investigation on Physicochemical Characteristics of a Nanoliposome-Based System for Dual Drug Delivery.Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer.Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk

P2860

Q16880225-34743FB9-E362-47AC-BC07-98B966BAA245 Q17577870-FBD5564A-73D8-4F6B-A6E2-C204AF9ED8B4 Q28872477-6F79CB75-BB53-46AC-8370-5C01BD4372E2 Q52392673-CAC43BF1-B26C-4AF7-B7F3-E123AB353E54 Q54798460-F3E75087-2DB0-4A6E-AE0F-7D1F1FE9F94D Q54798468-7F8C6D0C-95D9-4543-8CBC-6012461EBF90 Q54798471-D4C99569-B9AA-45A2-9822-B9E638EEC14A Q54881530-B79D91E3-80A9-4426-82D4-57878DC97653 Q54881536-90473C65-CB56-48F2-B2F7-6DA510B88477 Q54881570-ABBE2008-8963-4860-9F0F-F74D02B587AF Q54881587-E9DB9DF7-6E74-47D4-BC2B-F0231F1AD713 Q54881618-7516281A-E513-4105-8858-D1AE78BB26A0 Q54881712-0B5E5CFC-4FD0-4CF7-9A04-EA9B820AAD02 Q54881772-71432D10-9195-4230-B371-63F35DAE4B75 Q54895774-5E52925E-75F0-48C6-9434-6472BF191335 Q54904578-3E781FE5-6C27-4425-8642-7D9D7686BEBB Q54904639-204B5151-E047-4FE4-805F-A0EA99C72FC9 Q54970827-8CC8D84D-3327-4AF3-B51D-F1B1EFC7D540 Q54970832-7E2EC90D-D1BC-483B-9FF4-39B6DEC82F6F Q54970841-CD618AAA-1EB7-433C-991C-9367286224BB Q54970845-ADC23D2C-03D2-446B-9464-023FF4172BA1 Q54970848-355CE96D-6C70-4E2B-84A5-AC1558029A79 Q54971341-2C85C535-A11B-42B7-BA0D-A8DCA3010F7E Q54996119-543A18E7-98ED-4164-A6F9-9ACCB59AD430 Q7390592-31BC31C9-CAC1-498D-816D-D859FB6CBFCD

P1343

Q21132473-A7ABB74E-BA92-4AAB-B811-920D5B1A27E9 Q28828213-E007A6BF-B407-4CED-8E0D-518D76B67825 Q33728086-B6A487B1-820F-4F7B-ADA4-DAF284DF1C17 Q35000261-FE4E8135-801C-4291-9FD3-16671F601877 Q35236726-38161366-7D97-4BA2-9F70-EC84A01921A9 Q35287890-BC159445-5D74-4EFA-B192-5A1FA7FEE417 Q35620990-D3887FAC-5131-4A9A-A917-330A2B3F70E3 Q35812762-7C86D624-58DC-452E-B4DA-8227962E1307 Q35911470-2DD28413-6678-428A-ABE1-3A70108DB4A3 Q36289944-87C2997A-F3E2-44BB-AA45-457E4A7AA9E0 Q36678970-0B57E270-68C4-465A-AEB9-FBE2691C31AD Q36706840-0F1323BE-FFA5-4FA6-8C02-2BA00615A237 Q36721489-B370EC14-B87A-4C34-978F-4D894A562767 Q37536796-E81337CB-6FC6-4190-8BD8-70FDD68A7949 Q37548974-41A4EEB9-32E8-455C-97DD-8F0B2B67D919 Q37584321-4EA53911-B553-47DA-9E1A-B3C6ADCE9E04 Q37620662-D4271143-F6AA-408B-976A-42EF1C83FF47 Q38735131-903EB456-CEA3-451E-AF48-A67A232D913F Q38925460-EB713B2F-27AE-438E-B464-F867A9C783BB Q39173155-3FF3699D-1382-46A6-A673-8F35E6A80994 Q41411741-FC6EAE35-4615-4BBC-87D9-65E99527927C Q41916780-B788EE7C-09CC-4FF1-A8CF-EAF4B861B40D Q47099602-DCAC7AAD-C0F8-4FA0-9933-57CF1AE279DA Q50268380-149364DE-0BA9-4A2D-AAC2-CF23B113DF2A Q52726773-A6B363DF-D5F6-4887-890B-6C2033A7C493 Q53090999-FAB0989A-8300-4282-B931-EDC93E6C979B Q55207437-7BF383CF-2016-44FF-9672-033230B262A6 Q55646151-1E1621C4-A1E0-4D3A-91D0-51661882F8A5 Q58721369-9BF21046-B229-4ED1-B29C-686586200FE6 Q58791244-AB27C368-D1EE-4C3E-82AE-5B5705B921CC

P2860

Molecular characterisation of cell line models for triple-negative breast cancers.

http://www.wikidata.org/entity/Q34476551

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Molecular characterisation of cell line models for triple-negative breast cancers.

@ast

Molecular characterisation of cell line models for triple-negative breast cancers.

@en

Molecular characterisation of cell line models for triple-negative breast cancers.

@nl

type

label

Molecular characterisation of cell line models for triple-negative breast cancers.

@ast

Molecular characterisation of cell line models for triple-negative breast cancers.

@en

Molecular characterisation of cell line models for triple-negative breast cancers.

@nl

prefLabel

Molecular characterisation of cell line models for triple-negative breast cancers.

@ast

Molecular characterisation of cell line models for triple-negative breast cancers.

@en

Molecular characterisation of cell line models for triple-negative breast cancers.

@nl

P1433

Q34476551-C625702F-2691-496D-8159-BC16CF241B54

P1476

Q34476551-F782C747-C0D3-40D2-8E06-51E2B36ADBCC

P2093

Q34476551-420D238C-E098-4EB0-A053-3E9865BDCC5F

Q34476551-4BC172BD-F482-4633-B40F-1A057F4846DB

Q34476551-58E9851F-72A5-4886-819D-96F6F0942AF0

Q34476551-A08905C3-293F-4C5B-AFCF-6FA17BDCF9EC

Q34476551-C08C340E-D913-4BF5-9A8D-2F3F22CA9E3E

Q34476551-CB712198-2104-48B7-8710-BEDAFA5EC4C0

Q34476551-D529E388-AD7F-495D-B771-744F4834B2D3

P2860

Q34476551-0478AD77-A7DA-4E38-A9DE-DC6FD1B2670F

Q34476551-06B007B6-0986-4EAE-BF23-062635A57461

Q34476551-06EBD84E-C5CF-4955-B0F6-EBFBA8D8DB90

Q34476551-06FB4357-B9DA-4359-91E4-86182D64CB50

Q34476551-107DC622-F5B8-4902-BE6D-74FE9616A1B7

Q34476551-1F5218E4-E9D6-4252-B4E8-CF66B0FB9647

Q34476551-1F8439D7-F12C-436E-BD5D-AEAFFF6AC1A0

Q34476551-22EC5766-158D-40B6-A1FB-5FC375D8EFB9

Q34476551-2B1CB59A-E83B-4D84-9C74-5C38EAACDA88

Q34476551-33EAAA6E-A55A-4D57-8A9E-340F7B0EFABE

P2888

Q34476551-6C25BFDB-8886-47D8-97ED-262BC8F0DCE0

P304

Q34476551-7087EDD1-53DD-4A70-909B-8EB368BE0746

P31

Q34476551-67DFE794-35DB-4A2F-9173-36DCA5571080

P356

Q34476551-5949D739-FFB7-4D27-949B-AF9C9EBF9E10

P407

Q34476551-29761B6C-D7B1-4DB1-91B8-47F6FDFFEBC6

P4510

Q34476551-006D914A-A1EE-4537-A91A-A9AE238501E8

Q34476551-0B9B37A5-5C6C-4CAB-9841-C3341086988E

Q34476551-38D103B2-7654-47A5-9CE1-201297EBCEEA

Q34476551-3C1C72AF-28D3-4F44-8C8E-C197F9AFBA0C

Q34476551-5CEA33F4-E30A-4047-B4CF-8F6BA372A603

Q34476551-6B2BD4A1-C173-4EB1-950D-7EB29F8A0123

Q34476551-790F25D7-CB39-49B8-BB5E-09D40387BB6B

Q34476551-8B2DD433-7C59-41DF-A5A0-8186D746F860

Q34476551-964FA96F-AA20-4857-B0AE-3C108488E964

Q34476551-A01D48C0-F407-4517-9D1C-C3CF01172A4A

P478

Q34476551-B67D0D39-8D7E-404B-840E-2BDDD9DE4C1E

P50

Q34476551-2E1BD4A1-73CB-40AF-889D-F81D3D66DA60

P577

Q34476551-A1916E3D-B565-48A4-BD6C-D9CA701ECD6A

P5875

Q34476551-170B1099-96D2-4FA0-83E1-E8479CCF6D15

P6179

Q34476551-53986A9B-AA6D-4CEE-8708-9D043364A703

P698

Q34476551-5664EE32-7D80-4496-B336-25EA69AAA6A1

P921

Q34476551-4A0A9733-70D3-42D8-8B60-6C16B868673F

P932

Q34476551-5471F63A-0273-44B7-B857-79F8695FEFAA

P356

1471-2164-13-619

P1433

P1476

Molecular characterisation of cell line models for triple-negative breast cancers.

@en

P2093

Alan Mackay

http://www.w3.org/2001/XMLSchema#string

Andrew Tutt

http://www.w3.org/2001/XMLSchema#string

Anita Grigoriadis

http://www.w3.org/2001/XMLSchema#string

Elodie Noel

http://www.w3.org/2001/XMLSchema#string

Jessica Frankum

http://www.w3.org/2001/XMLSchema#string

Pei Jun Wu

http://www.w3.org/2001/XMLSchema#string

Rachel Natrajan

http://www.w3.org/2001/XMLSchema#string

P2860

An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ

The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells

Significance analysis of microarrays applied to the ionizing radiation response

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Determination of stromal signatures in breast carcinoma.

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

Relevance of breast cancer cell lines as models for breast tumours: an update

DNA copy number alterations and expression of relevant genes in triple-negative breast cancer

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

P2888

1471-2164-13-619

P304

619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2164-13-619

http://www.w3.org/2001/XMLSchema#string

P407

P4510

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Reis-Filho

P577

2012-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233417701

http://www.w3.org/2001/XMLSchema#string

P6179

1046480543

http://www.w3.org/2001/XMLSchema#string

P698

23151021

http://www.w3.org/2001/XMLSchema#string

P921

P932

3546428

http://www.w3.org/2001/XMLSchema#string